Krawczuk-Rybak Maryna, Kuźmicz Marta, Wysocka Jolanta
Department of Pediatric Oncology, Medical University of Białystok, Poland.
Pediatr Nephrol. 2005 Jun;20(6):782-5. doi: 10.1007/s00467-005-1839-3. Epub 2005 Mar 22.
Renal function tests (cystatin C, serum and urine creatinine, creatinine clearance, serum and urine beta(2)-microglobulin, microalbuminuria, osmolality) were performed in 21 children at the diagnosis and during the treatment for acute lymphoblastic leukemia (ALL) (group I) and in 37 children (group II) treated for ALL 3.9+/-3.7 years before the study. The results were compared to 20 healthy children. Mean values of renal tests were in normal range at all points of analysis in groups I and II compared to the control group. Transitory higher cystatin C values (but in normal range) were observed after methotrexate administration and after the end of treatment. Deteriorated renal function was observed in one child during the treatment (after each protocol) and in five children treated previously for ALL. In conclusion, combined treatment for ALL is not associated with severe or long-term impairment of renal function.
对21例急性淋巴细胞白血病(ALL)患儿在诊断时及治疗期间进行了肾功能检查(胱抑素C、血清和尿肌酐、肌酐清除率、血清和尿β2-微球蛋白、微量白蛋白尿、渗透压)(第一组),并对37例在研究前3.9±3.7年接受ALL治疗的患儿(第二组)进行了检查。将结果与20例健康儿童进行比较。与对照组相比,第一组和第二组在所有分析点的肾功能检查平均值均在正常范围内。甲氨蝶呤给药后及治疗结束后观察到胱抑素C值短暂升高(但在正常范围内)。治疗期间(每个方案后)有1例患儿及既往接受ALL治疗的5例患儿出现肾功能恶化。总之,ALL的联合治疗与严重或长期肾功能损害无关。